biostudies-literatureLiu HFudan University “Star of Tomorrow” Famous Doctor Training ProjectGrants from Shanghai Excellent Academic LeaderShanghai Sailing ProgramChina National Natural Science Funds116https://www.ebi.ac.uk/biostudies/studies/S-EPMC8935813biostudies-literatureUnknown13(1)<h4>Backgrounds</h4>Patients with AICLI constitute a considerable proportion of NO-CLI patients and cannot be treated with surgical or endovascular treatment. Although cell therapy has shown satisfactory results in treating AICLI, research comparing the efficacy of treatment with the 2 kinds of cell products is rare. The aim of this study was to report the 5-year outcomes of a randomized single-blinded noninferiority trial (Number: NCT02089828) on peripheral blood mononuclear cells (PBMNCs) and purified CD34⁺ cells (PCCs) transplantation for treating angiitis-induced critical limb ischemia (AICLI).<h4>Methods</h4>A randomized single-blinded non-inferiority trial (Number: NCT02089828) was performed. Fifty patients were randomized 1:1 to the PBMNCs and PCCs groups. Efficacy outcomStem cell research & therapyThe peripheral blood mononuclear cells versus purified CD34⁺ cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis-a randomized single-blinded non-inferiority trial.PMC8935813201919XD140120082000452819704078190042620YF1406600Liu HFang YLiu YGu SPan TFang GJiang XFu WDong ZLiu PWei ZChen BfalseThe peripheral blood mononuclear cells versus purified CD34⁺ cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis-a randomized single-blinded non-inferiority trial.<h4>Backgrounds</h4>Patients with AICLI constitute a considerable proportion of NO-CLI patients and cannot be treated with surgical or endovascular treatment. Although cell therapy has shown satisfactory results in treating AICLI, research comparing the efficacy of treatment with the 2 kinds of cell products is rare. The aim of this study was to report the 5-year outcomes of a randomized single-blinded noninferiority trial (Number: NCT02089828) on peripheral blood mononuclear cells (PBMNCs) and purified CD34⁺ cells (PCCs) transplantation for treating angiitis-induced critical limb ischemia (AICLI).<h4>Methods</h4>A randomized single-blinded non-inferiority trial (Number: NCT02089828) was performed. Fifty patients were randomized 1:1 to the PBMNCs and PCCs groups. Efficacy outcom2022-01-01T00:00:00Z2022 Mar2025-04-26T22:28:11.686Z2024-11-09T02:18:28.094ZS-EPMC89358133531396710.1186/s13287-022-02804-4